

**Study Number:** MOG08002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** Bisphenol AF  
**CAS Number:** 1478-61-1

**Date Report Requested:** 05/14/2020  
**Time Report Requested:** 08:05:22  
**Lab:** RTI

**Study Number:**

MOG08002B

**Study Gender:**

Both

**PWG Approval Date**

See web page for date of PWG Approval

**Study Number:** MOG08002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** Bisphenol AF  
**CAS Number:** 1478-61-1

**Date Report Requested:** 05/14/2020  
**Time Report Requested:** 08:05:22  
**Lab:** RTI

**F1 Male: Subchronic Male**

	Phase Day	Treatment Groups (ppm)			
		0	338	1125	3750
Urea Nitrogen (mg/dl) Percent of Control	PND 115 - 119	21.9 ± 0.8 (10)	20.1 ± 1.1 (10) 91.8	21.9 ± 0.8 (10) 100.0	21.6 ± 1.2 (9) 98.4
Creatinine (mg/dl) Percent of Control	PND 115 - 119	0.49 ± 0.03 (10)	0.51 ± 0.02 (10) 104.1	0.47 ± 0.02 (10) 95.9	0.48 ± 0.01 (9) 97.5
Glucose (mg/dl) Percent of Control	PND 115 - 119	419.9 ± 19.6 (10)	467.2 ± 33.0 (10) 111.3	427.9 ± 16.1 (10) 101.9	429.0 ± 37.2 (9) 102.2
Total Protein (g/dl) Percent of Control	PND 115 - 119	6.80 ± 0.06 (10) *	6.62 ± 0.08 (10) 97.4	6.60 ± 0.08 (10) 97.1	6.56 ± 0.06 (9) * 96.4
Globulin (g/dL) Percent of Control	PND 115 - 119	3.39 ± 0.04 (10) **	3.29 ± 0.05 (10) 97.1	3.24 ± 0.05 (10) * 95.6	3.20 ± 0.05 (9) ** 94.4
A/G Ratio Percent of Control	PND 115 - 119	1.01 ± 0.01 (10) *	1.01 ± 0.01 (10) 100.7	1.04 ± 0.01 (10) 103.1	1.05 ± 0.02 (9) 104.3
Albumin (g/dl) Percent of Control	PND 115 - 119	3.41 ± 0.03 (10)	3.33 ± 0.04 (10) 97.7	3.36 ± 0.05 (10) 98.5	3.36 ± 0.03 (9) 98.4
Cholesterol (mg/dl) Percent of Control	PND 115 - 119	94.3 ± 4.0 (10) **	87.7 ± 4.5 (10) 93.0	75.2 ± 3.2 (10) ** 79.7	58.8 ± 4.1 (9) ** 62.3
Triglyceride (mg/dl) Percent of Control	PND 115 - 119	154.7 ± 12.7 (10)	177.2 ± 13.9 (10) 114.5	172.8 ± 14.0 (10) 111.7	191.1 ± 15.2 (9) 123.5
Alkaline Phosphatase (U/L) Percent of Control	PND 115 - 119	220.0 ± 9.8 (10)	190.3 ± 15.1 (10) 86.5	208.7 ± 10.4 (10) 94.9	232.3 ± 20.4 (9) 105.6
Bile salt/acids (umol/L) Percent of Control	PND 115 - 119	32.7 ± 4.4 (10) **	25.3 ± 3.8 (10) 77.3	19.7 ± 2.8 (10) * 60.1	6.0 ± 0.3 (9) ** 18.5

**Study Number:** MOG08002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** Bisphenol AF  
**CAS Number:** 1478-61-1

**Date Report Requested:** 05/14/2020  
**Time Report Requested:** 08:05:22  
**Lab:** RTI

**F1 Female: Subchronic Females**

	Phase Day	Treatment Groups (ppm)			
		0	338	1125	3750
Urea Nitrogen (mg/dl)	PND 116 - 120	19.3 ± 0.6 (10)	18.4 ± 1.0 (10)	19.6 ± 0.6 (10)	22.1 ± 2.1 (10)
Percent of Control			95.3	101.6	114.5
Creatinine (mg/dl)	PND 116 - 120	0.48 ± 0.02 (10)	0.44 ± 0.02 (10)	0.45 ± 0.02 (10)	0.50 ± 0.01 (10)
Percent of Control			91.7	93.8	104.2
Glucose (mg/dl)	PND 116 - 120	408.9 ± 15.8 (10)	397.1 ± 13.2 (10)	372.0 ± 17.8 (10)	390.7 ± 15.4 (10)
Percent of Control			97.1	91.0	95.5
Total Protein (g/dl)	PND 116 - 120	6.50 ± 0.10 (10)	6.32 ± 0.11 (10)	6.41 ± 0.09 (10)	6.65 ± 0.11 (10)
Percent of Control			97.2	98.6	102.3
Globulin (g/dL)	PND 116 - 120	3.02 ± 0.06 (10) **	3.01 ± 0.07 (10)	3.10 ± 0.06 (10)	3.31 ± 0.07 (10) **
Percent of Control			99.7	102.6	109.6
A/G Ratio	PND 116 - 120	1.15 ± 0.02 (10) **	1.10 ± 0.02 (10)	1.07 ± 0.02 (10) **	1.01 ± 0.02 (10) **
Percent of Control			95.6	92.6	87.6
Albumin (g/dl)	PND 116 - 120	3.48 ± 0.05 (10)	3.31 ± 0.04 (10)	3.31 ± 0.05 (10)	3.34 ± 0.05 (10)
Percent of Control			95.1	95.1	96.0
Cholesterol (mg/dl)	PND 116 - 120	100.1 ± 2.4 (10) **	87.5 ± 3.6 (10) *	74.5 ± 5.7 (10) **	63.2 ± 4.8 (10) **
Percent of Control			87.4	74.4	63.1
Triglyceride (mg/dl)	PND 116 - 120	101.4 ± 11.6 (10) *	108.0 ± 11.3 (10)	119.2 ± 20.2 (10)	167.8 ± 21.3 (10) *
Percent of Control			106.5	117.6	165.5
Alanine Aminotransferase (U/L)	PND 116 - 120	76.2 ± 3.9 (10)	86.7 ± 5.1 (10)	81.2 ± 4.2 (10)	83.5 ± 3.2 (10)
Percent of Control			113.8	106.6	109.6
Alkaline Phosphatase (U/L)	PND 116 - 120	199.4 ± 11.3 (10)	182.5 ± 16.4 (10)	211.2 ± 12.6 (10)	215.2 ± 17.0 (10)
Percent of Control			91.5	105.9	107.9

**Study Number:** MOG08002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** Bisphenol AF  
**CAS Number:** 1478-61-1

**Date Report Requested:** 05/14/2020  
**Time Report Requested:** 08:05:22  
**Lab:** RTI

---

**F1 Female: Subchronic Females**

---

	Phase Day	Treatment Groups (ppm)			
		0	338	1125	3750
Creatine Kinase (U/L)	PND 116 - 120	95.7 ± 5.7 (10) *	124.6 ± 15.8 (10)	171.1 ± 54.5 (10)	187.2 ± 35.4 (10) *
Percent of Control			130.2	178.8	195.6
Sorbitol Dehydrogenase (U/L)	PND 116 - 120	17.7 ± 1.1 (10)	18.8 ± 1.3 (10)	19.6 ± 0.8 (10)	19.7 ± 1.5 (10)
Percent of Control			106.3	110.8	111.4
Bile salt/acids (umol/L)	PND 116 - 120	23.3 ± 6.2 (10)	25.9 ± 5.5 (10)	23.4 ± 3.2 (10)	10.5 ± 1.8 (10)
Percent of Control			111.4	100.6	45.2

**Study Number:** MOG08002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** Bisphenol AF  
**CAS Number:** 1478-61-1

**Date Report Requested:** 05/14/2020  
**Time Report Requested:** 08:05:22  
**Lab:** RTI

#### LEGEND

---

Values given as mean  $\pm$  SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

PND - Postnatal Day, adults post-weaning

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

Male alanine aminotransferase, sorbitol dehydrogenase and creatine kinase data were excluded from analyses due to clinical anomalies.

**\*\* END OF REPORT \*\***